UNSPSC 51343800: Combination antivirals

This classification denotes combination drugs used in the prophylaxis or therapy of viral diseases (or diseases that viruses cause), which operate by preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Typical combination antiviral constituents are abacavir, efavirenz, emtricitabine, interferon alfa-2b, lamivudine, lopinavir, and peginterferon.

UNSPSC 51343800 Combination antivirals is a Class code that does not align with the work actually being solicited under it by state and local governments. Recent opportunities tagged to this code involve naloxone and drug deactivation systems, direct-to-manufacturer pharmacy programs, medical and first aid supplies for emergency response, and generic pharmaceuticals and over-the-counter products — none of which fall within the combination antiviral scope the code nominally describes. The mismatch suggests either inconsistent coding practices in the jurisdictions tagging these opportunities or a systematic misalignment between the taxonomy and current procurement practice in this pharmaceutical category.

State and local jurisdictions posting under this code include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), city fire departments (City of Tampa), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving multiple states including Oregon). Representative recent opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries (due July 26, 2023); the City of Tampa's sheltered-market IFB for medical and first aid supplies for the Fire Department Rescue Division, estimated at $700,000.00, with a 5% SLBE discount (due March 13, 2026); the Texas HHS Commission's RFI on direct-to-manufacturer prescription programs (due April 3, 2026); and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products through authorized wholesalers, with proposals due March 26, 2026. The code shows recent activity concentrated in Florida and Texas, with multistate cooperative vehicle participation spanning Oregon and Minnesota. Given the disconnect between code definition and actual procurement scope, firms should verify coding accuracy before pursuing opportunities tagged to this classification.